DRUG TRANSPORT IN THE BRAIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 452

221. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ. 1995. Clinical and
neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging
16:1-4.
222. Tamai I, Tsuji A. 2000. Transporter-mediated permeation of drugs across the blood-brain
barrier. J Pharm Sci 89:1371-1388.
223. Kido Y, Tamai I, Ohnari A, Sai Y, Kagami T, Nezu J-I, Nikaido H, Hashimoto N,
Asano M, Tsuji A. 2001. Functional relevance of carnitine transporter OCTN2 to
brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier.
J Neurochem 79:959-969.
224. Yabuuchi H, Tamai I, Sakamoto K, Sai Y, Tsuji A, Nezu J-I, Oku A, Shimane M.
1999. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and
pH-dependent transport of organic cations. J Pharmacol Exp Ther 289:768-773.
225. Brooks H, Krahenbuhl S. 2001. Identification and tissue distribution of two differentially
spliced variants of the rat carnitine transporter OCTN2. FEBS Lett 508:175-180.
226. Nezu J-I, Oku A, Shimane M, Tamai I, Ohashi R, Yabuuchi H, Sai Y, Tsuji A, Hashimoto
N, Nikaido H, et al. 1999. Primary systemic carnitine deficiency is caused by mutations
in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 21:91-94.
227. Wagner CA, L ukewille U, Kaltenbach S, Moschen I, Broer A, Risler T, Broer S, Lang
F. 2000. Functional and pharmacological characterization of human Na+-carnitine
cotransporter hOCTN2. Am J Physiol Renal Physiol 279:F584-F591.
228. Wu X, Huang W, Seth P, Rajan DP, Leibach FH, Ganapathy V, Prasad PD, Chen J,
Conway SJ. 1999. Functional characteristics and tissue distribution pattern of organic
cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp
Ther 290:1482-1492.
229. Ohashi R, Tamai I, Yabuuchi H, Sai Y, Tsuji A, Nezu J-I, Oku A, Shimane M.
1999. Na + -dependent carnitine transport by organic cation transporter (OCTN2): Its
pharmacological and toxicological relevance. J Pharmacol Exp Ther 291:778-784.
230. Inano A, Sai Y, Tsuji A, Tamai I, Nikaido H, Hasimoto N, Asano M. 2003. Acetyl-
L-carnitine permeability across the blood-brain barrier and involvement of carnitine
transporter OCTN2. Biopharm Drug Dispos 24:357-365.
231. Lamhonwah A-M, Tein I, Ackerley CA, Tilups A, Edwards VD, Wanders RJ. 2005.
OCTN3 is a mammalian peroxisomal membrane carnitine transporter. Biochem Biophys
Res Commun 338:1966-1972.
232. Von Lubitz DKJE, Carter MF, Beenhakker M, Lin RC, Jacobson KA. 1995. Adenosine:
A prototherapeutic concept in neurodegeneration. Ann N Y Acad Sci 765:163-178.
233. Baldwin SA, Mackey JR, Cass CE, Young JD. 1999. Nucleoside transporters: Molecular
biology and implications for therapeutic development. Mol Med Today 5:216-224.
234. Griffith DA, Jarvis SM. 1996. Nucleoside and nucleobase transport systems of

mammalian cells. Biochim Biophys Acta Rev Biomembr 1286:153-181.
235. Fox IH, Kelley WN. 1978. The role of adenosine and 2 -deoxyadenosine in mammalian
cells. Annu Rev Biochem 47:655-686.
236. Tremblay GC, Jimenez U, Crandall DE. 1976. Pyrimidine biosynthesis and its regulation
in the developing rat brain. J Neurochem 26:57-64.
237. Kraupp M, Marz R. 1995. Nucleobase and nucleoside transport in mammalian cells.
Wien Klin Wochenschr 107:677-680.